Management of Elevated LDH in Patients on Venetoclax

Introduction to LDH Elevation

The National Comprehensive Cancer Network recommends evaluating patients with elevated LDH for tumor lysis syndrome (TLS), disease progression, or infection, as LDH is a key marker of TLS 1
TLS risk is highest during venetoclax dose escalation, particularly at the 20 mg and 50 mg dose levels during the initial 5-week ramp-up period, according to the National Comprehensive Cancer Network 1

A complete metabolic panel with focus on potassium, uric acid, phosphorus, calcium, and creatinine should be assessed to evaluate for TLS, as recommended by the National Comprehensive Cancer Network 1
The American Society of Clinical Oncology suggests evaluating for neutropenia, thrombocytopenia, or anemia with a complete blood count, given the high risk of these conditions in patients on venetoclax 1

The National Comprehensive Cancer Network recommends temporarily holding venetoclax immediately until metabolic abnormalities resolve if TLS is confirmed, with aggressive IV hydration and management of electrolyte abnormalities 1
Rasburicase should be considered if uric acid is significantly elevated, according to the National Comprehensive Cancer Network 1

The National Comprehensive Cancer Network suggests continuing venetoclax with enhanced monitoring if the patient is clinically stable, with increased hydration and monitoring of blood chemistries pre-dose and 6-8 hours post-dose at next dose escalation 1
Infection should be evaluated, given the high infection rate of 84% in patients on venetoclax, as reported in Leukemia 2, 3

The National Comprehensive Cancer Network recommends reducing venetoclax dose by 75% if the patient is on posaconazole or other strong CYP3A4 inhibitors, as these agents significantly increase venetoclax exposure and TLS risk 2, 3

Antibacterial and antifungal prophylaxis should be considered when venetoclax is combined with hypomethylating agents, according to Leukemia 2, 3
Allopurinol or xanthine oxidase inhibitor should be continued, as recommended by the National Comprehensive Cancer Network, and adequate hydration should be maintained 1

Venetoclax can cause rapid tumor cell death leading to tumor lysis syndrome (TLS), which may result in acute kidney injury, as suggested by the National Comprehensive Cancer Network 4, 5

High tumor burden, particularly in patients with certain types of cancer, increases TLS risk, according to the National Comprehensive Cancer Network 4, 5
Impaired baseline renal function is a significant risk factor for venetoclax-associated kidney injury, as noted by the National Comprehensive Cancer Network 4, 5
Concomitant use of strong CYP3A4 inhibitors increases venetoclax exposure and potentially TLS risk, as reported in Leukemia 6

Gradual dose ramp-up is essential, with a recommended starting dose of 20 mg and gradual increase to target dose over 5 weeks, as suggested by the National Comprehensive Cancer Network 4, 5, 7
Aggressive hydration is critical, with oral hydration and intravenous hydration as needed, according to the National Comprehensive Cancer Network 4, 5
Prophylactic uric acid-lowering agents should be started 2-3 days prior to venetoclax initiation, as recommended by the National Comprehensive Cancer Network 4, 5

For patients at high risk of TLS, consider inpatient treatment during dose escalation with more intensive monitoring, as suggested by the National Comprehensive Cancer Network 4, 8, 9
If TLS develops, temporarily hold venetoclax and manage electrolyte abnormalities aggressively, according to the National Comprehensive Cancer Network 8, 9
Consider dose interruptions to allow for hematologic recovery in patients with good response but persistent cytopenias, as reported in Leukemia 6